What one share of ProPhase Labs holds
We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.
ProPhase Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$1.71 |
| Cash and investments | $0.00 |
| Book value | −$0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $15.47 | −$3.00 | $0.16 | $0.19 | — | $10.98 |
| 2010 | $10.15 | $2.45 | $0.11 | −$2.59 | — | $9.42 |
| 2011 | $11.78 | −$1.83 | $0.20 | −$1.63 | — | $7.57 |
| 2012 | $15.10 | −$0.70 | $0.21 | −$4.07 | — | $7.28 |
| 2013 | $18.54 | $0.30 | $0.33 | $0.51 | — | $7.82 |
| 2014 | $13.16 | −$4.67 | $0.19 | −$2.10 | — | $6.74 |
| 2015 | $1.54 | −$2.20 | $0.44 | −$2.57 | — | $5.17 |
| 2016 | $2.46 | −$1.68 | $0.38 | −$0.66 | — | $3.49 |
| 2017 | $6.29 | $25.86 | $0.13 | −$1.94 | — | $28.61 |
| 2018 | $11.52 | −$1.53 | $0.12 | −$1.98 | — | $14.29 |
| 2019 | $8.54 | −$2.72 | $0.20 | −$0.92 | — | $9.70 |
| 2020 | $12.52 | −$1.83 | $1.46 | −$3.69 | — | $9.10 |
| 2021 | $42.97 | $3.95 | $2.30 | −$9.70 | $3.00 | $37.86 |
| 2022 | $65.76 | $10.24 | $2.10 | $13.21 | — | $39.25 |
| 2023 | $20.33 | −$9.75 | $1.21 | −$8.12 | — | $27.37 |
| 2024 | $3.38 | −$26.68 | $0.45 | −$9.22 | — | $2.46 |
| 2025 | $0.51 | −$1.74 | $0.00 | −$0.98 | — | $0.39 |
Common questions about ProPhase Labs
How much does one share of ProPhase Labs earn?
Over the last 12 months, ProPhase Labs lost $1.71 for each share on $0.29 of sales.
Does ProPhase Labs pay a dividend?
ProPhase Labs didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ProPhase Labs’s book value per share?
ProPhase Labs’s book value is negative (−$0.22 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of ProPhase Labs have?
Each share of ProPhase Labs has $0.00 of cash and investments, as of June 30, 2026.
Has ProPhase Labs bought back shares?
ProPhase Labs’s share count rose about 563% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.